Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Lymphoma

An Introduction to Lymphoma

Lymphoma is one of the ten most common malignancies worldwide. While some lymphomas are curable, the treatment of relapsed and refractory disease remains a substantial challenge. Recent advances have led to the development of a number of new treatment strategies, including novel antibodies targeting surface antigens, small molecular inhibitors targeting oncogenic signalling pathways and tumour suppressors, and immune checkpoint inhibitors. Chimeric antigen receptor (CAR) T-cells offer the potential for personalised therapy. The emergence of so many new therapeutic options have raised challenges in terms of optimal sequencing and combined approaches, and have highlighted the need for biomarkers to predict therapeutic response.

Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

Our supporting partners do not constitute an endorsement of the content on this page.

15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Expert insights on new and emerging approaches to optimize the management of steroid-refractory cGvHD.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Dr Matthew Lunning, Professor Charalambos Andreadis, Dr Tara Graff

Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL

41 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch haemato-oncology experts discuss updates in managing R/R mantle cell lymphoma with CAR T-cell therapy.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch haemato-oncology experts discuss updates in R/R follicular lymphoma, with a focus on CAR T-cell therapy.

Mark CompleteCompleted
BookmarkBookmarked
Nitin Chilakamarri, Karla Olmedo, Elizabeth A Brem

Marginal zone lymphoma subtypes Marginal zone lymphoma (MZL) is an indolent non-Hodgkin lymphoma (NHL) that accounts for 5.0%–10.0% of NHLs.1 There are three subtypes of MZL: extranodal (including mucosa-associated lymphoid tissue [MALT]), splenic and nodal.1 Extranodal MZL (EMZL) is the most ...

Mark CompleteCompleted
BookmarkBookmarked
Allison Rosenthal, Javier Munoz

B-cell signalling pathways are critical regulators of B-cell development, expansion, and survival and function via various mediators, including Src family kinases (SFKs), spleen tyrosine kinase, Bruton’s tyrosine kinase (BTK) and phosphatidylinositol 3 kinase (PI3K) (Figure 1).1,2 BTK, a member of ...

Mark CompleteCompleted
BookmarkBookmarked
Krishna Goparaju, Allison Winter, Paolo F Caimi

The addition of rituximab to chemotherapy provides an overall survival benefit in aggressive lymphomas,1 whereas for indolent lymphoma subtypes this addition has resulted in improvements in progression-free survival.2 For more than two decades, immunotherapy with monoclonal ‘naked’ antibodies targeting CD20 ...

Mark CompleteCompleted
BookmarkBookmarked

Allogeneic haematopoietic stem cell transplant (allo-HSCT) remains a potential curative therapeutic option for patients with refractory/relapsed Hodgkin lymphoma (HL) in whom an autologous peripheral blood stem-cell transplantation (PBSCT) has failed. This is explained by the additional benefit of a ...

45 mins
touchPANEL DISCUSSION
Mark CompleteCompleted
BookmarkBookmarked

Learn about patient selection for chimeric antigen receptor (CAR) T-cell therapy, adverse event management and the latest developments in CAR T-cell therapies for B-cell malignancies from experts in the field.

Load More...
Close Popup